Niagen Bioscience, Inc. (NAGE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.17+1.93%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Maintain stable profit margins and improve expense outlook: operating margin 2.4% vs stable target; net margin 3.2% vs 12.4% TTM.
Niagen Bioscience grows revenue about 18% yearly. It plans $31M to $36M revenue in 2026. The company expanded its buyback program to $20M. Profit margins and costs are stable. Growth is supported by rising sales investment.
The company missed earnings recently and faces a 31% stock drop. Sales growth could slow below 18%. Cost control efforts may fail. Buybacks might not offset weak fundamentals.
The price is about 25% above our fair value near $2.72. Analysts expect 18% revenue growth, which is reflected in the price. Our view aligns with this growth but notes risks from recent earnings misses.
Breaks if: Buyback program is reduced or not executed as planned
Breaks if: expense outlook worsens or margins decline materially in FY26
YoY revenue growth falls below 18% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment is in a stable company with a focus on growth. NAGE is navigating a high-risk environment but has shown strong recent financial performance, making it a candidate for long-term observation.
The current valuation suggests a stretched position compared to peers, indicating that the market has some expectations for growth. However, the fragility is low, as the market does not fully reflect the potential risks associated with weak execution.
Management is focused on growing the e-commerce business and increasing sales and marketing investments, which aligns with their growth strategy. However, the near-term risk of missing earnings remains significant due to the high miss probability in the industry.
The future performance of NAGE will depend on guidance updates from management, sector performance from key players, and broader economic indicators like job reports. Any negative guidance or worsening economic conditions could impact sentiment significantly.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Management plans to increase sales and marketing spending to support brand growth and new vertical launches in 2026.
Stated in 2 of last 2 quarters. Sales and marketing expense increased by $1.6 million in Q1 2026 compared to prior year, reflecting management's plan to increase investment in brand growth and new verticals. The trajectory shows delivering increased spending consistent with stated priorities.
“Sales & marketing investment expected to increase in 2026.”
“Sales and marketing expense increased $1.6 million, driven by higher advertising and marketing spend.”
Overall, NAGE is positioned for potential growth, but investors should remain cautious due to the inherent risks in the current environment. Not investment advice.